Your browser doesn't support javascript.
loading
Drug-induced eRF1 degradation promotes readthrough and reveals a new branch of ribosome quality control.
Gurzeler, Lukas-Adrian; Link, Marion; Ibig, Yvonne; Schmidt, Isabel; Galuba, Olaf; Schoenbett, Julian; Gasser-Didierlaurant, Christelle; Parker, Christian N; Mao, Xiaohong; Bitsch, Francis; Schirle, Markus; Couttet, Philipp; Sigoillot, Frederic; Ziegelmüller, Jana; Uldry, Anne-Christine; Teodorowicz, Wojciech; Schmiedeberg, Niko; Mühlemann, Oliver; Reinhardt, Jürgen.
Afiliação
  • Gurzeler LA; Department of Chemistry, Biochemistry and Pharmaceutical Sciences, University of Bern, Bern, Switzerland; Graduate School for Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland.
  • Link M; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Ibig Y; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Schmidt I; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Galuba O; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Schoenbett J; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Gasser-Didierlaurant C; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Parker CN; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Mao X; Novartis Institutes for BioMedical Research, Cambridge, MA, USA.
  • Bitsch F; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Schirle M; Novartis Institutes for BioMedical Research, Cambridge, MA, USA.
  • Couttet P; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Sigoillot F; Novartis Institutes for BioMedical Research, Cambridge, MA, USA.
  • Ziegelmüller J; Department of Chemistry, Biochemistry and Pharmaceutical Sciences, University of Bern, Bern, Switzerland; Graduate School for Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland.
  • Uldry AC; Proteomics and Mass Spectrometry Core Facility, Department for BioMedical Research, University of Bern, Bern, Switzerland.
  • Teodorowicz W; Department of Chemistry, Biochemistry and Pharmaceutical Sciences, University of Bern, Bern, Switzerland; Graduate School for Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland.
  • Schmiedeberg N; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Mühlemann O; Department of Chemistry, Biochemistry and Pharmaceutical Sciences, University of Bern, Bern, Switzerland. Electronic address: oliver.muehlemann@unibe.ch.
  • Reinhardt J; Novartis Institutes for BioMedical Research, Basel, Switzerland. Electronic address: juergen.reinhardt@novartis.com.
Cell Rep ; 42(9): 113056, 2023 09 26.
Article em En | MEDLINE | ID: mdl-37651229
ABSTRACT
Suppression of premature termination codons (PTCs) by translational readthrough is a promising strategy to treat a wide variety of severe genetic diseases caused by nonsense mutations. Here, we present two potent readthrough promoters-NVS1.1 and NVS2.1-that restore substantial levels of functional full-length CFTR and IDUA proteins in disease models for cystic fibrosis and Hurler syndrome, respectively. In contrast to other readthrough promoters that affect stop codon decoding, the NVS compounds stimulate PTC suppression by triggering rapid proteasomal degradation of the translation termination factor eRF1. Our results show that this occurs by trapping eRF1 in the terminating ribosome, causing ribosome stalls and subsequent ribosome collisions, and activating a branch of the ribosome-associated quality control network, which involves the translational stress sensor GCN1 and the catalytic activity of the E3 ubiquitin ligases RNF14 and RNF25.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Biossíntese de Proteínas / Fibrose Cística Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Cell Rep Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Suíça

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Biossíntese de Proteínas / Fibrose Cística Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Cell Rep Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Suíça